Compare Adaptive Biotechnologies Corp (ADPT) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Mattel Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while Mattel Inc trades at $15.05 (market cap $4.21B). The key difference: Adaptive Biotechnologies Corp and Mattel Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MAT | |
|---|---|---|
Market Cap | $4.05B | $4.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $22.16 |
52-Week Low | $12.30 | $13.05 |
Enterprise Value | $4.12B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Mattel (MAT) trades at $14.79, up 2.07% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with revenue growth of 10% but an earnings miss due to higher costs. Valuation appears reasonable with P/E of 11.03 and P/S of 0.82, while profitability metrics show strong ROE of 20.5% despite margin pressures from increased advertising expenses.
The stock presents a balanced opportunity with analyst consensus leaning bullish (53% buy ratings) but faces near-term headwinds from cost inflation and discretionary spending pressures. Long-term growth drivers include toy-based entertainment partnerships and digital gaming expansion, though execution risks and market volatility require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
